gram-negative

(redirected from Gram-negative bacterial infections)
Also found in: Dictionary, Thesaurus, Encyclopedia.

gram-negative

 [gram-neg´ah-tiv]
losing the stain or decolorized by alcohol in Gram's method of staining; see Gram stain. This is a primary characteristic of bacteria having a cell wall composed of a thin layer of peptidoglycan covered by an outer membrane of lipoprotein and lipopolysaccharide.

gram-neg·a·tive

(gram-neg'ă-tiv), In this expression gram begins with lowercase g but Gram stain takes an uppercase G.
Refers to the inability of a type of bacterium to resist decolorization with alcohol after being treated with crystal violet. However, following decolorization, these bacteria can be readily counterstained with safranin, imparting a pink or red color to them when viewed by light microscopy. This reaction is usually an indication that the outer structure of the bacterium consists of a cytoplasmic (inner) membrane surrounded by a relatively thin peptidoglycan layer, which in turn is surrounded by an outer membrane. See: Gram stain.

gram-negative

/gram-neg·a·tive/ (-neg´ah-tiv) losing the stain or decolorized by alcohol in Gram's method of staining, characteristic of bacteria having a cell wall surface more complex in chemical composition than the gram-positive bacteria.

gram-negative

or

Gram-negative

(grăm′nĕg′ə-tĭv)
adj.
Of, relating to, or being a bacterium that does not retain the violet stain used in the Gram stain method.

gram-negative

Etymology: Hans C.J. Gram, Danish physician, 1853-1938; L, negare, to say no
having the pink color of the counterstain used in Gram's method of staining microorganisms. This property is a primary method of characterizing organisms in microbiology. Some of the most common gram-negative pathogenic bacteria are Bacteroides fragilis, Brucella abortus, Escherichia coli, Haemophilus influenzae, Klebsiella pneumoniae, Neisseria gonorrhoeae, Proteus vulgaris, Pseudomonas aeruginosa, Salmonella typhi, Shigella dysenteriae, and Yersinia pestis.

gram-neg·a·tive

(gram-neg'ă-tiv)
Refers to the inability of a bacterium to resist decolorization with alcohol after being treated with Gram crystal violet. However, following decolorization, these bacteria can be readily counterstained with safranin, imparting a pink or red color to the bacterium when viewed by light microscopy.
See: Gram stain

Gram-negative

see GRAM'S STAIN.

Gram-negative

Refers to the property of many bacteria that causes them to not take up color with Gram's stain, a method which is used to identify bacteria. Gram-positive bacteria which take up the stain turn purple, while Gram-negative bacteria which do not take up the stain turn red.

gram-neg·a·tive

(gram-neg'ă-tiv)
Refers to the inability of a type of bacterium to resist decolorization with alcohol after being treated with crystal violet.

gram-negative,

n having the pink color of the counterstain used in Gram's method of staining microorganisms. Staining property is a common method of classifying bacteria. See also Gram's stain.

gram-negative

said of bacteria that are decolorized by alcohol in Gram's method of staining (see gram's stain), and are thus stained only with the counter stain (usually red). Gram-negative bacteria have a much thinner layer of peptidoglycan in the cell wall than Gram-positive bacteria.
References in periodicals archive ?
Coverage of the Gram-Negative Bacterial Infections pipeline on the basis of route of administration and molecule type.
The company said Zavicefta (ceftazidime-avibactam) is a fixed-dose combination antibacterial that was developed to treat serious Gram-negative bacterial infections.
We are pleased that the data from this Phase 2 trial support plazomicin's potential utility as an important new treatment option for patients with certain serious Gram-negative bacterial infections," said Kenneth J.
The company said AVYCAZ is an antibiotic developed to treat certain serious Gram-negative bacterial infections.
Cubist is developing CXA-201 as a first-line intravenous therapy for the treatment of serious Gram-negative bacterial infections, including those caused by multi-drug resistant Pseudomonas aeruginosa.
According to the company, LpxC inhibitors have the potential to fill an important unmet medical need in the treatment of antibiotic-resistant gram-negative bacterial infections, including bacterial pneumonias and bloodstream infections and additionally have the potential to treat infections caused by biothreat pathogens.
Cubist is developing CXA-201 as a first-line intravenous therapy for the treatment of serious Gram-negative bacterial infections in the hospital, including those caused by multi-drug resistant Pseudomonas aeruginosa.
Steve Gilman, PhD, Cubist's Chief Scientific Officer, said, "We are pleased with the safety and microbiological response data from this study, which we believe supports the further development of CXA-201 as a useful therapeutic agent for the treatment of certain serious Gram-negative bacterial infections.
CXA-201 is being developed as a first-line intravenous therapy for the treatment of certain serious Gram-negative bacterial infections in the hospital, including those caused by multi-drug resistant P.
Multidrug-resistant Gram-negative bacterial infections are an area of significant unmet medical need, particularly in acute care settings.
Supports Development of Novel Compounds to Treat Multi-Drug Resistant Gram-Negative Bacterial Infections -
There is an urgent need for the development of new antibiotics to treat these and other gram-negative bacterial infections," said Steven Porter, Chairman and CEO of Ceragenix Pharmaceuticals.

Full browser ?